Peptide Publications Archive
Showing items in Drug Discovery · Clear filter
Targeting Protein Interactions
Arora Lab
Researchers in the Arora Group at New York University, published in Chemical Reviews, have assembled a comprehensive blueprint for designing inhibitors of protein-protein interactions. …
Metabolic Resilience
Labs at Genentech
Researchers at Genentech, published in the Journal of Medicinal Chemistry, present a comprehensive perspective on the strategies that medicinal chemists and DMPK scientists now …
Selective Protein Degraders
Tang Group
Researchers in the Tang Group at the University of Wisconsin-Madison, in collaboration with colleagues at NovoNordisk, published in Advanced Science, have engineered an insulin-like …
Helical Peptide Discovery
Suga and Katoh Labs
A team led by Hiroaki Suga and Takayuki Katoh at the University of Tokyo extended their engineered tRNA system, tRNAPro1E2, to incorporate five achiral dαAAs …
Supra-Bivalent Inhibitors
Sengoku and Suga Labs
A collaboration between the laboratories of Professor Hiroaki Suga at the University of Tokyo and Professor Toru Sengoku at Yokohama City University has developed a …
Conditional Miniprotein Activation
Oller-Salvia Lab
Protein therapeutics have transformed treatment of diseases from cancer to immune disorders, yet many targets appear not only at diseased sites but also in healthy …
ACE-Inhibitory Peptides
Beys-da-Silva Lab
Hypertension remains the leading cause of premature death worldwide, yet one in five affected adults achieve adequate blood pressure control. Angiotensin-converting enzyme inhibitors represent one …
Mirror-Image Hunters
Denisov/Dijkgraaf Labs
Chemokines make frustrating drug targets. These small signaling proteins orchestrate immune cell migration during inflammation, making them attractive therapeutic targets for conditions ranging from atherosclerosis …
Modeling Selectivity
Miller Lab
Chiral sulfur compounds are gaining traction in drug discovery. Unlike their achiral counterparts, molecules with stereogenic sulfur centers often show improved potency and selectivity. IFM …
Helical Hijackers
Cai Lab
The Wnt/β-catenin signaling pathway governs embryonic development, stem cell maintenance, and tissue homeostasis. When aberrantly activated, it drives colorectal cancer and other malignancies. Inside the …
Covalent Peptide Libraries
Bode Lab
Covalent inhibitors provide potent and durable target engagement, with approved drugs such as ibrutinib and osimertinib validating the approach. These compounds exploit electrophilic warheads to …
Peptide Aggregation Blockers
Wright Lab
The misfolding and aggregation of transthyretin, TTR, a serum protein responsible for transporting thyroxine and retinol binding protein, underlies a class of amyloid diseases that …
Engineered Lasso Peptides
Burk Lab
A major barrier to durable responses with PD-1/PD-L1 checkpoint inhibitors is the activation of immunosuppressive TGF-β within the tumor microenvironment. This immunosuppression is driven in …
Coagulation Trigger
Ruvo Lab
Hemostasis begins with a handshake. When vascular damage exposes tissue factor, TF, to the bloodstream, factor VII, FVII, latches on, instantly engaging the extrinsic pathway …
Allosteric Turns
Sampaio-Dias Lab
Disorders of the central nervous system linked to dysregulation of dopamine D2 receptors — including depression, drug addiction, Parkinson’s disease, and movement disorders — …
Degrading Light
Lou Lab
Targeted protein degradation has rapidly matured into a transformative drug discovery approach, offering ways to dismantle proteins once deemed undruggable. While classical proteolysis-targeting chimeras, PROTACs, …
Blocking Metastasis
Kennedy Lab
Metastasis remains the leading cause of cancer mortality, and one driver of this process is the actin cytoskeleton remodeling mediated by WASF3, a protein strongly …
Peptide Anti Obesity 2.0
David Lab
Obesity is a leading contributor to global disease burden and a primary risk factor for type 2 diabetes, yet current treatments often lack specificity and …
Conjugation Chemistry
Kwon Lab
Traumatic brain injury, TBI, remains a profound and unresolved clinical challenge, responsible for long-term disability in both civilian and military populations. The lack of effective …
Capturing the Uncatchable
Arora Lab
In a major step forward, researchers in the Arora Group at the New York University, have now developed a rationally designed proteomimetic receptor capable of …